Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Regional disparities and socioeconomic determinants of pediatric lymphoid leukemia mortality in Brazil from 2000-2021

Bárbara Sarni Sanches, Ciana Botelho, Isadora Lima Oliveira et al. Nov 03, 2025 pp. 8094-8094 10.1182/blood-2025-8094

Abstract Introduction: Leukemias are the most frequent cancers in childhood and adolescence, and socioeconomic factors are known to be relat...

Factor v inhibits factor x activation by the tissue factor-factor VIIa complex

Megan Jewell, Dougald Monroe, Keith Neeves Nov 03, 2025 pp. 1283-1283 10.1182/blood-2025-1283

Abstract Background: Factor V (FV) has pro- and anticoagulant roles in the regulation of coagulation. This is reflected in the paradoxical o...

Outcomes after relapse for adolescent and young adult patients with ALL: Results from the Children's oncology group

Jordyn Griffin, Lingyun Ji, Alice Dang et al. Nov 03, 2025 pp. 548-548 10.1182/blood-2025-548

Abstract Background Outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) are improvi...

Integrated genomic and tumor microenvironment subtyping refines risk stratification in primary central nervous system lymphoma

Xianggui Yuan, Qian Luo, Yurong Huang et al. Nov 03, 2025 pp. 5304-5304 10.1182/blood-2025-5304

Abstract Purpose: Primary CNS lymphoma (PCNSL) remains a therapeutic challenge due to limited precision medicine approaches and suboptimal r...

The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL)

Kelly Davison, Joseph Unger, Hongli Li et al. Nov 03, 2025 pp. 2738-2738 10.1182/blood-2025-2738

Abstract Introduction Patients (pts) with newly diagnosed, advanced-stage cHL are at risk for poor health-related quality of life (HRQoL) du...

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Uday Popat, Roland Bassett, Amin Alousi et al. Nov 03, 2025 pp. 378-378 10.1182/blood-2025-378

Abstract Background: Patients with high-risk acute myeloid leukemia (AML) continue to experience poor outcomes despite undergoing stem cell...

Donor-derived secondary CAR-T cell therapy for relapsed leukemia following initial CAR-T bridged to allogeneic transplantation: Efficacy and safety analysis

Yiqing Ren, Weiming Zhang, Guoqing Wei et al. Nov 03, 2025 pp. 5941-5941 10.1182/blood-2025-5941

Abstract Background Relapse following CAR-T therapy bridged to allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a t...

Myeloid sarcoma: A population based retrospective study

umair bajwa, Hassan Ali, Shammas Bajwa et al. Nov 03, 2025 pp. 6912-6912 10.1182/blood-2025-6912

Abstract Introduction Myeloid sarcoma (MS) is an extramedullary form of acute myeloid leukemia (AML). It is a high grade hematologic maligna...

More than a decade without treatment: Time to first treatment in CLL in a chilean cohort

Macarena Roa, Sofia Pacheco, Claudia Gajardo et al. Nov 03, 2025 pp. 7429-7429 10.1182/blood-2025-7429

Abstract Background: Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease, with time to first treatment (TTFT) being a c...

Comparative 3- and 5-year outcomes among first-line imatinib, dasatinib, and nilotinib in chronic myeloid leukemia: A real world analysis

Nnamdi Omenuko, Chidiebube Ugwu, Kalan Patel et al. Nov 03, 2025 pp. 7288-7288 10.1182/blood-2025-7288

Abstract Background: First-line tyrosine kinase inhibitor (TKI) selection in chronic myeloid leukemia (CML) impacts both molecular response...

Seasonal variation in chronic and acute pain in patients with sickle cell disease

Galia Pollock, Susanna Curtis, Brittany McCrary et al. Nov 03, 2025 pp. 1190-1190 10.1182/blood-2025-1190

Abstract Introduction: Pain events are the most common symptom of sickle cell disease (SCD) and many patients with SCD also develop chronic...

A reduced-frequency targeted combination regimen ( DVd-lite) for the treatment of newly diagnosed multiple myeloma with renal impairment: A single-center, open-label, prospective clinical study

Dongfeng Zeng, Maoyuan Xiang, Huan Xie Nov 03, 2025 pp. 7519-7519 10.1182/blood-2025-7519

Abstract Objective: This study aimed to evaluate the efficacy and safety of the reduced-frequency targeted combination regimen DVd-lite (dar...

Impact of race on the incidence, diagnosis and outcomes of pregnancy-associated venous thromboembolism: A nested case-control study

Yan Xu, Michael Pugliese, Leslie Skeith et al. Nov 03, 2025 pp. 1340-1340 10.1182/blood-2025-1340

Abstract Background: Venous thromboembolism (VTE) is a potentially life-threatening complication of pregnancy. While diagnostic delays are a...

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)

Utsav Joshi, Fatima Tuz Zahra, Pujan Patel et al. Nov 03, 2025 pp. 4630-4630 10.1182/blood-2025-4630

Abstract Background: Survival outcomes in AML are influenced by multiple patient- and disease-related factors, including age, performance st...

Apply-PNH: Analysis of complement pathway biomarkers provides evidence for pharmacodynamic response in PNH patients who receive oral iptacopan monotherapy versus continuing anti-C5 therapy

Régis Peffault de Latour, Carlos de Castro, Richard Kelly et al. Nov 03, 2025 pp. 4979-4979 10.1182/blood-2025-4979

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hemolytic disorder characterized by complement-mediated...

Outcomes of pediatric patients transplanted for B-ALL with high-risk cytogenetics- a 20-year experience from LMIC setting

Duaa Zandaki, Eman Khattab, Hasan Hashem et al. Nov 03, 2025 pp. 7831-7831 10.1182/blood-2025-7831

Abstract Introduction Cytogenetics are increasingly utilized in guiding risk stratification and treatment in pediatric A...

Functional characterization of Sec14L4 in hudep-2 and mouse knockout models reveals its essential role in erythropoiesis.

Mouna Ouchari, Audrey Belot, Akueba Bruce et al. Nov 03, 2025 pp. 607-607 10.1182/blood-2025-607

Abstract Background Red blood cell (RBC) transfusion is a common intervention for hospitalized patients, particularly those with sickle cell...

Plasma proteomic profiles predict future non-Hodgkin lymphoma in healthy adults

Qing Luo, Yi Luo, Li Yu Nov 03, 2025 pp. 5334-5334 10.1182/blood-2025-5334

Abstract Background: Non-Hodgkin lymphoma (NHL) is the most common type of lymphoma, with diffuse large B-cell lymphoma (DLBCL) and follicul...

Trends in second primary malignancies in myelofibrosis pre- and post-JAK inhibitor era: A surveillance, epidemiology and end-Results database study

Mohammad Ebad Ur Rehman, Samra Sohail, Bana Antonios et al. Nov 03, 2025 pp. 3825-3825 10.1182/blood-2025-3825

Abstract Background Ruxolitinib, the first JAK inhibitor approved for the treatment of myelofibrosis in 2012, was...

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Hua-Jay Cherng, Drew Gerber, Chijioke Nze et al. Nov 03, 2025 pp. 471-471 10.1182/blood-2025-471

Abstract Background: For LS-DLBCL, clinical trials (FLYER, LYSA/GOELAMS 02-03, LYSA LNH09-1B, S1001) have shown that 4 cycles of rituximab,...

The immunomodulatory effects of IRF3/7 transcription factors and IL10 in ALK+ anaplastic large cell lymphoma (ALCL)

Georgios Rassidakis, Dora Trogrlic, Ying Yang et al. Nov 03, 2025 pp. 5336-5336 10.1182/blood-2025-5336

Abstract Introduction: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) is a distinct aggressive T-cell non-Ho...

Endothelial cell-derived mitochondrial transfer to Acute Myeloid Leukemia alters global gene expression to confer chemoresistance

Niraj Dhakal, Fedra Suarez Perez, Romarico Gonzales Hernandez et al. Nov 03, 2025 pp. 5015-5015 10.1182/blood-2025-5015

Abstract Acute myeloid leukemia (AML) exhibits high relapse rates, suggesting the existence of robust mechanisms that protect leukemic cells...

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy

Elias Jabbour, David Sallman, Debbie Briseno-Toomey et al. Nov 03, 2025 pp. 3429-3429 10.1182/blood-2025-3429

Abstract Background and Significance Newly diagnosed (ND) acute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar)is associated with po...

Combined factor v and VIII deficiency: A mucocutaneous bleeding phenotype driven predominantly by factor VIII – a retrospective study of 34 patients

Anusha Thangaraja, Nitty Mathews, Tulasi Geevar et al. Nov 03, 2025 pp. 312-312 10.1182/blood-2025-312

Abstract BACKGROUND Combine factor V and VIII deficiency (F5F8D) is a rare autosomal recessive bleeding disorder (<1/million) caused b...

RIT1 mutations in myeloid neoplasms

Lukas Ronner, Guang Yang, David Lieberman et al. Nov 03, 2025 pp. 5628-5628 10.1182/blood-2025-5628

Abstract Background: Constitutive activation of the RAS/MAPK cascade due to mutations in canonical RAS-family proteins, upstream tyrosine ki...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page